
ECOG-ACRIN Cancer Research Group/X
Aug 1, 2025, 02:30
How Well Osimertinib Works to Control EGFR-Positive Lung Cancer – ECOG-ACRIN Cancer Research Group
ECOG-ACRIN Cancer Research Group shared a post on X:
“The PrE1702 Real World Data research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive Lung Cancer in patients not participating in a clinical trial.
More posts featuring ECOG-ACRIN Cancer Research Group on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32